Oncolytics Biotech
Developing pelareorep, an IV delivered I-O virus, promoting an inflamed tumor: waking the immune system.
- Healthcare
- biotechnology
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $20.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| CAD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 2215 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (4220 %) | (96 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (3633 %) | (109 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Oncolytics Biotech Inc. is a biotechnology company focused on developing innovative cancer treatments. The company's core product, pelareorep, is a unique immunotherapy designed to awaken the immune system and unlock its antitumor potential. Unlike other immunotherapies that require direct injection into tumors, pelareorep is delivered intravenously and is systemically active, meaning it can target cancer cells throughout the body. This makes it a versatile treatment option for various types of cancer. Oncolytics Biotech serves patients with cancer, aiming to improve their quality of life by offering more time with family and for personal passions. The company operates in the biotechnology and healthcare markets, primarily targeting oncology. Its business model involves the development and commercialization of pelareorep, either as a standalone treatment or in combination with other therapies, to enhance its efficacy. Revenue is generated through partnerships, licensing agreements, and potential future sales of pelareorep.
Keywords: immunotherapy, cancer treatment, pelareorep, intravenous delivery, systemic activity, oncology, biotechnology, healthcare, tumor targeting, patient quality of life.